¼¼°èÀÇ ¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´Ü ½ÃÀå
Pediatric Cardiac Tumor Diagnostics
»óǰÄÚµå : 1777418
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 376 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´Ü ½ÃÀåÀº 2030³â±îÁö 9¾ï 4,610¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 6¾ï 6,270¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´Ü¼¼°è ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 6.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 9¾ï 4,610¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿ø¹ß¼º ½ÉÀå Á¾¾çÀº CAGR 4.9%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 5¾ï 6,690¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2Â÷¼º ½ÉÀå Á¾¾ç ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 8.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 8,060¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR9.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´Ü ½ÃÀåÀº 2024³â¿¡ 1¾ï 8,060¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 9.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 9,100¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.1%¿Í 5.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.0%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Èñ±ÍÁúȯÀº ¾î¶»°Ô °ü·Ã¼ºÀÌ ³ô¾ÆÁ³À»±î? ¼Ò¾Æ ½ÉÀå Á¾¾çÀÇ Á¶±â Áø´Ü¿¡ ´ëÇÑ °ü½É Áõ°¡

¼Ò¾Æ ½ÉÀå Á¾¾çÀº ¿µÀ¯¾Æ¿Í ¼Ò¾Æ¿¡¼­ ¹ß°ßµÇ´Â ½ÉÇ÷°ü Áúȯ Áß °¡Àå µå¹°Áö¸¸ °¡Àå ½É°¢ÇÑ Áúȯ Áß ÇϳªÀ̸ç, Áø´Ü°ú Ä¡·á¿¡ ½É°¢ÇÑ ¹®Á¦¸¦ ¾ß±âÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¼Ò¾Æ Àα¸¿¡¼­ ¿ø¹ß¼º ½ÉÀå Á¾¾çÀÇ ¹ß»ý·üÀº 0.2% ¹Ì¸¸À¸·Î ÃßÁ¤µÇÁö¸¸, Áø´ÜÀÌ ´Ê¾îÁö°Å³ª ³õÄ¡¸é »ý¸íÀ» À§ÇùÇÏ°í ºÎÁ¤¸Æ, ½ÉºÎÀü ¶Ç´Â ½ÉÀå µ¹¿¬»ç·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¿ª»çÀûÀ¸·Î Áø´ÜÀº ´ë°³ ¿ì¹ßÀûÀ¸·Î ÀÌ·ç¾îÁö¸ç, °ü·Ã ¾ø´Â Áõ»ó °Ë»ç³ª ºÎ°Ë Áß¿¡ ¹ß°ßµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ±×·¯³ª ÇöÀç´Â ¼Ò¾Æ½ÉÀåÇÐ ÇÁ·Î±×·¥ÀÇ È®´ë¿Í ÀÓ»óÀÇÀÇ ÀÎ½Ä °³¼±À¸·Î Á¶±â¿¡ Á¤È®ÇÑ Áø´ÜÀ¸·Î ÀüȯµÇ°í ÀÖ´Â Ãß¼¼ÀÔ´Ï´Ù. ÅÂ¾Æ ¹× ½Å»ý¾Æ ½ÉÃÊÀ½ÆÄ °Ë»çÀÇ ¹ßÀüÀ¸·Î žƱ⿡µµ ½ÉÀå Á¾¾ç, ƯÈ÷ Å©±â°¡ Å©°Å³ª ½ÉÀå ±â´ÉÀ» ÀúÇØÇÏ´Â Á¾¾çÀ» ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Ⱦ¹®±ÙÁ¾, ¼¶À¯Á¾, Á¡¾×Á¾Àº ¼Ò¾Æ¿¡¼­ °¡Àå ÈçÇÏ°Ô ¹ß°ßµÇ´Â ¾ç¼º Á¾¾çÀ¸·Î, °¢°¢ Áø´Ü ÇÁ·ÎÆÄÀÏÀÌ ´Ù¸£±â ¶§¹®¿¡ ¿µ»ó Áø´Ü°ú ÇØ¼®¿¡ °íµµ·Î Á¶Á¤µÈ Á¢±ÙÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÓ»ó¿¡¼­ ¼Ò¾Æ°ú ÀÇ»ç¿Í ¼øÈ¯±â Àü¹®ÀÇ´Â ¼ÒÀ½, û»öÁõ, Àç¹ß¼º ½Ç½Å°ú °°Àº ¹Ì¹¦ÇÑ Â¡Èĸ¦ ¾Ë¾ÆÂ÷¸± ¼ö ÀÖµµ·Ï ÈÆ·Ã¹Þ¾Ò½À´Ï´Ù. ƯÈ÷ ½ÉÀå Ⱦ¹®±ÙÁ¾°ú Á¾Á¾ ¿¬°üµÈ °áÀý¼º °æÈ­Áõ ÁõÈıº°ú °°Àº ÁõÈıºÀÇ °æ¿ì, À¯Àü »ó´ãÀÇ ÅëÇÕÀÌ ÁøÇàµÇ¾î Á¶±â Áø´Ü¿¡ Àû±ØÀûÀÎ ÃþÀ» Ãß°¡Çϰí ÀÖ½À´Ï´Ù. »ýÁ¸À²ÀÌ Çâ»óµÇ°í ÀÓ»ó °¨½Ã°¡ °­È­µÊ¿¡ µû¶ó ¼Ò¾Æ½ÉÀåÁ¾¾ç Áø´ÜÇÐÀº ¹ÝÀÀÀû ¿µ¿ª¿¡¼­ ¿¹¹æÀû ¿µ¿ªÀ¸·Î ÀüȯµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ¼Ò¾Æ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ±× Á߿伺ÀÌ Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

¿µ»ó Áø´ÜÀÌ ¹ßÀüÀÇ Á߽ɿ¡ ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡? ¼Ò¾Æ ½ÉÀå Áø´ÜÀÇ ±â¼ú Çõ¸í ޱ¸

¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´ÜÀÇ ±â¼úÀû »óȲÀº ºñħ½ÀÀû ¿µ»ó Áø´ÜÀÌ ¹ß°ß°ú ¸ð´ÏÅ͸µÀÇ ¾ç¸é¿¡¼­ Áß½ÉÀûÀÎ ¿ªÇÒÀ» ÇÏ´Â µî ±ØÀûÀ¸·Î ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ½ÉÃÊÀ½ÆÄ °Ë»ç´Â ¾ÈÀü¼º, È޴뼺, °íÇØ»óµµ ½Ç½Ã°£ À̹Ì¡ ±â´ÉÀ¸·Î ÀÎÇØ ¿©ÀüÈ÷ ÃÊ±â Æò°¡ÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. 3D ½ÉÃÊÀ½ÆÄ ¹× µµÇ÷¯ ¹æ½ÄÀÇ Çõ½ÅÀº Á¾¾çÀÇ Å©±â, À§Ä¡, Ç÷¿ªÇп¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ »ó¼¼ÇÑ ÇØºÎÇÐÀû ¹× ±â´ÉÀû ÅëÂû·ÂÀ» Á¦°øÇÔÀ¸·Î½á Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ½ÉÀå ÀÚ±â°ø¸í¿µ»ó(MRI)Àº ƯÈ÷ Á¾¾çÀÇ À¯ÇüÀ» °¨º°Çϰí Ç÷ÀüÀ̳ª ´Ù¸¥ Á¾±«¿Í ±¸º°ÇÒ ¼ö ÀÖ´Â ¿ì¼öÇÑ Á¶Á÷ Ư¼ºÀ» Á¦°øÇÔÀ¸·Î½á Áß¿äÇÑ º¸Á¶ ÀåÄ¡·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. T1, T2 ¸ÅÇÎ ¹× Èı⠰¡µ¹¸®´½ Áõ°­°ú °°Àº °í±Þ ½ÃÄö½ÌÀº Á¾¾çÀÇ ´ÜÀý°ú ħÀ±À» º¸´Ù Á¤È®ÇÏ°Ô ±×·Á³¾ ¼ö ÀÖ¾î ¼ö¼ú °èȹ ¹× À§Çè Æò°¡¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ½ÉÀå ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CT)Àº ¹æ»ç¼± ³ëÃâ¿¡µµ ºÒ±¸Çϰí, Á¾¾ç Çüųª °ü»óµ¿¸Æ ÇØºÎÇÐÀû ±¸Á¶ÀÇ ½Å¼ÓÇÑ 3D ½Ã°¢È­°¡ ÇÊ¿äÇÑ º¹ÀâÇϰųª ¸ðÈ£ÇÑ °æ¿ì¿¡ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿µ»ó ºÐ¼®¿¡ ÀΰøÁö´É°ú ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀ» µµÀÔÇÔÀ¸·Î½á, ƯÈ÷ 3Â÷ ¼Ò¾ÆÃ»¼Ò³â ÀÇ·á¼¾ÅÍ¿¡¼­´Â ÆÐÅÏ Àνİú Áø´Ü Ç¥ÁØÈ­¸¦ À§ÇÑ »õ·Î¿î ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. PET-MRI À¶ÇÕ¿µ»ó, Á¶¿µÁ¦ ÃÊÀ½ÆÄ µî ÇØºÎÇÐÀû Æò°¡¿Í ´ë»çÆò°¡ÀÇ °£±ØÀ» ¸Þ¿ì±â À§ÇÑ »õ·Î¿î ¿µ»ó±â¹ýµµ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû ¹ßÀüÀº Áø´ÜÀÇ ½Å·Ú¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, ¸¹Àº °æ¿ì ½ÉÀå Ä«Å×ÅÍ »ðÀÔÀ̳ª »ý°Ë°ú °°Àº ħ½ÀÀû ½Ã¼úÀÇ Çʿ伺À» °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù. ¿µ»ó Áø´ÜÀÌ ´õ¿í Á¤±³ÇØÁö°í µðÁöÅзΠÅëÇյʿ¡ µû¶ó ¿µ»óÀÇÇаú Àü¹®ÀÇ¿Í ¼Ò¾Æ½ÉÀåÀü¹®ÀÇÀÇ ¿ªÇÒÀº »ý¸í¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Á¾¾çÀ» Àû½Ã¿¡ Á¤È®ÇÏ°Ô Áø´ÜÇϱâ À§ÇØ º¸´Ù Çù·ÂÀûÀÌ°í µ¥ÀÌÅÍ Áß½ÉÀÇ ÆÄÆ®³Ê½ÊÀ¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

´ÙÁ÷Á¾ Çù·ÂÀÌ ¼Ò¾Æ ½ÉÀåÁ¾¾ç Áø´Ü ¿öÅ©Ç÷ο츦 À籸¼ºÇÒ ¼ö ÀÖÀ»±î?

¼Ò¾Æ ½ÉÀåÁ¾¾çÀÇ º¹ÀâÇÑ Æ¯¼ºÀ¸·Î ÀÎÇØ Áø´Ü, À§Çè °èÃþÈ­, Ä¡·á °æ·ÎÀÇ °£¼ÒÈ­¿¡ ÀÖ¾î ´ÙÇÐÁ¦Àû Çù·ÂÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´ÜÀº Á¾Á¾ ¼Ò¾Æ ½ÉÀå Àü¹®ÀÇ, ½ÉÀå ¿Ü°ú ÀÇ»ç, Á¾¾ç Àü¹®ÀÇ, ¹æ»ç¼± Àü¹®ÀÇ, º´¸®ÇÐÀÚ, º´¸®ÇÐÀÚ, À¯ÀüÇÐ Àü¹®ÀÇ, ÁßÁõ Ä¡·á Àü¹®ÀÇÀÇ ÇùÁøÀ¸·Î ÀÌ·ç¾îÁý´Ï´Ù. ÀÌ·¯ÇÑ ÆÀ ±â¹Ý Á¢±Ù¹ýÀº ÁÖ¿ä ¾î¸°ÀÌ º´¿ø°ú ½ÉÀå Àü¹® ½Ã¼³¿¡¼­ Ç¥ÁØ Ä¡·á¹ýÀ¸·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ¿µ»ó ¼Ò°ßÀ» °ËÅäÇϰí, ¼ö¼úÀÇ ½ÇÇà °¡´É¼ºÀ» Æò°¡Çϰí, ÈÄ¼Ó Á¶Ä¡ ÇÁ·ÎÅäÄÝÀ» °áÁ¤Çϱâ À§ÇØ ÀÌ·¯ÇÑ Àü¹® ºÐ¾ß·Î ±¸¼ºµÈ Á¾¾ç À§¿øÈ¸¸¦ ¼ÒÁýÇÏ´Â °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüÀÚ ÇÁ·ÎÆÄÀϸµÀº ƯÈ÷ Ä«´Ï ÄÞÇ÷º½º³ª °ñ¸° ÁõÈıº°ú °°Àº Áúȯ¿¡¼­ Áõ»ó ¿¬°ü¼º, À¯ÀüÀû µ¹¿¬º¯ÀÌ, ÀáÀçÀû Àç¹ß À§ÇèÀ» È®ÀÎÇϱâ À§ÇØ Áø´Ü¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. Á¾¾ç »ý°ËÀº ħ½ÀÀû Ư¼º°ú ±×¿¡ µû¸¥ À§Ç輺À¸·Î ÀÎÇØ ±Ý±â½ÃµÇ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ º´¸®Á¶Á÷ÇÐÀû ÅëÂû·ÂÀº ÀϹÝÀûÀ¸·Î ¿µ»óÁø´Ü°ú ÀÓ»ó µ¥ÀÌÅ͸¦ ÅëÇØ Ã߷е˴ϴÙ. ¼Ò¾Æ½ÉÀåÁ¾¾çÇÐÀÇ ºÎ»óÀº Àü¹® ºÐ¾ß¸¦ ³Ñ¾î¼± ÀÇ»ç°áÁ¤ °øÀ¯ÀÇ Çʿ伺À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á Ç÷§Æû°ú µðÁöÅÐ »ç·Ê °øÀ¯ µµ±¸´Â ƯÈ÷ ¼¼ÄÁµå ¿ÀÇǴϾðÀÌ ÇÊ¿äÇÑ Èñ±ÍÇϰųª ¸ðÈ£ÇÑ »ç·Ê¿¡ ´ëÇØ ½Ç½Ã°£À¸·Î Àü¹®°¡ ÆÐ³Î¿¡ ¿ø°ÝÀ¸·Î Âü¿©ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¼Ò¾Æ ½ÉÀåÁ¾¾ç ¹ß°ßÀÌ Á¤½ÅÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù´Â °ÍÀ» ÀνÄÇϰí, ºÎ¸ðµéÀÇ »ó´ã°ú ½É¸®»çȸÀû Áö¿øÀÌ Áø´Ü ¿©Á¤¿¡ Æ÷ÇԵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ´ÙÇÐÁ¦Àû Ä¡·á·ÎÀÇ Ã¼°èÀû ÀüȯÀº Áø´Ü ÀÏÁ¤°ú Á¤È®¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó »ýÁ¸°ú »îÀÇ ÁúÀ» ÃÖÀûÈ­ÇÏ´Â ¸ÂÃã Ä¡·á Àü·«À» ÃËÁøÇÕ´Ï´Ù. ÀÇ·á ±â°ü¿¡¼­ Ä¡·áÀÇ ÅëÇÕÀÌ °­Á¶µÇ¸é¼­ ¼Ò¾Æ ½ÉÀåÁ¾¾ç Áø´Ü ¿öÅ©Ç÷ο찡 º¸´Ù ÅëÇÕÀûÀ̰í, Çù·ÂÀûÀ̸ç, ȯÀÚ Áß½ÉÀûÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù.

¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº Áø´Ü Çõ½Å, ÀÓ»ó ÀÌ¿ë »ç·ÊÀÇ È®´ë, ¼ÒºñÀÚ ±â´ëÄ¡ÀÇ ÁøÈ­ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ 3D ½ÉÃÊÀ½ÆÄ, °íÀÚÀå ½ÉÀå MRI, ÇÏÀ̺긮µå À̹Ì¡ ±â¼úÀÇ º¸±ÞÀº Á¶±â ¹ß°ßÀ²°ú Áø´Ü Á¤È®µµ¸¦ Å©°Ô Çâ»ó½ÃÄÑ ½ÃÀå ħÅõ¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ Ãø¸é¿¡¼­´Â ¼Ò¾Æ Àü¹® º´¿ø, ÅÂ¾Æ ½ÉÀ庴 ÇÁ·Î±×·¥, ¼Ò¾Æ Á¾¾ç ¼¾ÅÍÀÇ º¸±ÞÀÌ È®´ëµÇ¸é¼­ °íÇØ»óµµ, ´ÙÁß ÆÄ¶ó¹ÌÅÍ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¿ä ¿øµ¿·ÂÀº ½ÉÀ庴ÇÐ ¿öÅ©Ç÷ο쿡 À¯ÀüÀÚ Áø´Ü°ú ºÐÀÚÁø´ÜÀÌ ÅëÇյǾî Á¾¾ç ¼ÒÀΰú °ü·Ã ÁõÈıºÀ» »çÀü¿¡ ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ¶ÇÇÑ Å¬¶ó¿ìµå ±â¹Ý ¿µ»ó °ü¸® ½Ã½ºÅÛ°ú AI °­È­ ºÐ¼® Ç÷§Æû¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº °øµ¿ Áø´ÜÀ» Áö¿øÇϰí, ÇØ¼® ¿À·ù¸¦ ÁÙÀ̸ç, ´Ù±â°ü ÀÇ·á ³×Æ®¿öÅ© °£ÀÇ º¸°í¸¦ °£¼ÒÈ­ÇÕ´Ï´Ù. ¼Ò¾Æ½ÉÀå Èñ±ÍÁúȯ¿¡ ´ëÇÑ ÀÓ»óÀÇÀÇ ÀÎ½Ä °³¼±°ú Áö¼ÓÀûÀÎ ±³À° ÇÁ·Î±×·¥ÀÌ ¿µ»óÁø´ÜÀ» À§ÇÑ ÀÇ·Ú ºóµµ¿Í Á¤È®µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å»ý¾Æ °ËÁø ¹× »êÀü °ËÁø¿¡ ´ëÇÑ ³ë·ÂÀÌ °¡¼ÓÈ­µÊ¿¡ µû¶ó ½ÉÀå Á¾¾çÀÌ ´õ ÀÏÂï Áø´ÜµÇ°í, ´õ ³ªÀº °³ÀÔ ½Ã±â¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Ãø¸é¿¡¼­´Â ºÎ¸ð°¡ ¼Ò¾Æ ÀÇ·á¿¡ ´ëÇÑ ÀÇ»ç°áÁ¤¿¡ Âü¿©ÇÏ°Ô µÇ¸é¼­ ºü¸£°í ºñħ½ÀÀûÀ̸ç Á¤È®ÇÑ Áø´Ü ¿É¼ÇÀ» ±â´ëÇÏ´Â °æÇâÀÌ °­ÇØÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼Ò¾Æ°ú ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ±¹Á¦ÀûÀÎ °øµ¿¿¬±¸´Â Áõ°Å¿¡ ±â¹ÝÇÑ Áø´Ü °¡À̵å¶óÀÎ °³¹ßÀ» ÃËÁøÇϰí, ±× °á°ú ÀÇ·á ½Ã½ºÅÛ Àü¹ÝÀÇ Àåºñ ¾÷±×·¹À̵å¿Í ÇÁ·ÎÅäÄÝ Ç¥ÁØÈ­¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ´Ù¾çÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¼Ò¾Æ ½ÉÀå Á¾¾ç Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Èñ±ÍÇÏÁö¸¸ Áß¿äÇÑ Áúȯ¿¡ ´ëÇÑ Á¢±Ù, ¹ß°ß ¹× °ü¸® ¹æ¹ýÀ» Àü ¼¼°èÀûÀ¸·Î À籸¼ºÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¾¾ç(¿ø¹ß¼º ½ÉÀå Á¾¾ç, 2Â÷¼º ½ÉÀå Á¾¾ç);À¯Çü(½ÉÀå ÃÊÀ½ÆÄ, ÀÚ±â°ø¸í¿µ»ó, ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ ½ºÄµ, ±âŸ);ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ¹× Ŭ¸®´Ð, Á¤ºÎ º¸°Ç±¹, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pediatric Cardiac Tumor Diagnostics Market to Reach US$946.1 Million by 2030

The global market for Pediatric Cardiac Tumor Diagnostics estimated at US$662.7 Million in the year 2024, is expected to reach US$946.1 Million by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Primary Cardiac Tumors, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$566.9 Million by the end of the analysis period. Growth in the Secondary Cardiac Tumors segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$180.6 Million While China is Forecast to Grow at 9.4% CAGR

The Pediatric Cardiac Tumor Diagnostics market in the U.S. is estimated at US$180.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$191.0 Million by the year 2030 trailing a CAGR of 9.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Pediatric Cardiac Tumor Diagnostics Market - Key Trends & Drivers Summarized

How Is Rare Becoming Relevant? The Surging Focus on Early Diagnosis of Pediatric Cardiac Tumors

Pediatric cardiac tumors are among the rarest but most serious cardiovascular abnormalities observed in infants and children, often presenting significant diagnostic and treatment challenges. While the incidence of primary cardiac tumors in the pediatric population is estimated at less than 0.2%, the implications of delayed or missed diagnosis can be life-threatening, leading to arrhythmias, heart failure, or sudden cardiac death. Historically, diagnosis was typically incidental, discovered during investigations for unrelated symptoms or during autopsies. However, there is now a clear shift towards early, targeted diagnostics driven by the expansion of pediatric cardiology programs and increased clinician awareness. Advances in fetal and neonatal echocardiography are enabling the detection of cardiac tumors even before birth, especially those with large sizes or those obstructing cardiac function. Rhabdomyomas, fibromas, and myxomas are the most common benign tumors found in children, each presenting distinct diagnostic profiles that necessitate a highly tailored approach to imaging and interpretation. In the clinical setting, pediatricians and cardiologists are increasingly trained to recognize subtle signs-such as murmurs, cyanosis, or recurrent syncope-that may warrant deeper investigation. The growing integration of genetic counseling, particularly in syndromes like tuberous sclerosis complex, which is frequently associated with cardiac rhabdomyomas, also adds a proactive layer to early diagnosis. As survival rates improve and clinical surveillance becomes more robust, pediatric cardiac tumor diagnostics are transitioning from a reactive to a preventative domain, underscoring their rising relevance in pediatric healthcare systems globally.

Why Is Imaging at the Heart of Progress? Exploring the Technological Revolution in Pediatric Cardiac Diagnostics

The technological landscape for pediatric cardiac tumor diagnostics has evolved dramatically, with non-invasive imaging modalities taking center stage in both detection and monitoring. Echocardiography remains the cornerstone of initial assessment due to its safety, portability, and high-resolution real-time imaging capabilities. Innovations in 3D echocardiography and Doppler modalities are enhancing diagnostic accuracy by providing detailed anatomical and functional insights into tumor size, location, and hemodynamic impact. Cardiac magnetic resonance imaging (MRI) has emerged as a critical adjunct, offering superior tissue characterization, particularly for differentiating between tumor types and distinguishing them from thrombi or other masses. Advanced sequences, such as T1 and T2 mapping and late gadolinium enhancement, are enabling more precise delineation of tumor margins and infiltration, crucial for surgical planning and risk assessment. Additionally, cardiac computed tomography (CT), despite its radiation exposure, is increasingly used in complex or ambiguous cases where rapid 3D visualization of tumor morphology and coronary anatomy is required. The incorporation of artificial intelligence and machine learning algorithms into image analysis is opening new avenues for pattern recognition and diagnostic standardization, particularly in tertiary pediatric centers. Emerging modalities such as PET-MRI fusion imaging and contrast-enhanced ultrasound are also being explored to bridge the gap between anatomical and metabolic assessment. These technological advances are not only improving diagnostic confidence but are also reducing the need for invasive procedures like cardiac catheterization or biopsy in many cases. As diagnostic imaging becomes more refined and digitally integrated, the role of radiologists and pediatric cardiologists is evolving into a more collaborative, data-driven partnership aimed at timely and precise diagnosis of these life-impacting tumors.

Is Multidisciplinary Collaboration Reshaping the Diagnostic Workflow for Pediatric Cardiac Tumors?

The complex nature of pediatric cardiac tumors has made multidisciplinary collaboration essential in streamlining diagnosis, risk stratification, and care pathways. A pediatric cardiac tumor diagnosis often triggers the coordinated involvement of pediatric cardiologists, cardiac surgeons, oncologists, radiologists, pathologists, geneticists, and critical care specialists. This team-based approach is becoming the standard of care at leading pediatric hospitals and specialized heart institutes. Tumor boards comprising these specialties are increasingly convened to review imaging findings, evaluate surgical feasibility, and decide on follow-up protocols. Furthermore, genetic profiling is being integrated into diagnostics to identify syndromic associations, inherited mutations, and potential recurrence risks, particularly in conditions like Carney complex or Gorlin syndrome. As tumor biopsies are often contraindicated due to their invasive nature and associated risks, histopathological insights are typically inferred from imaging and clinical data, making collaborative diagnostic interpretation all the more crucial. The rise of pediatric cardio-oncology as a sub-discipline is further highlighting the need for shared decision-making across specialties. Telemedicine platforms and digital case-sharing tools are also enabling remote participation of expert panels in real time, particularly for rare or ambiguous cases requiring second opinions. Parental counseling and psychosocial support are increasingly integrated into the diagnostic journey, recognizing the emotional impact of cardiac tumor detection in children. This systemic shift toward multidisciplinary care is not only improving diagnostic timelines and accuracy but also fostering individualized treatment strategies that optimize both survival and quality of life. With growing institutional emphasis on care integration, diagnostic workflows for pediatric cardiac tumors are becoming more cohesive, coordinated, and patient-centered.

The Growth in the Pediatric Cardiac Tumor Diagnostics Market Is Driven by Several Factors…

The growth in the pediatric cardiac tumor diagnostics market is driven by several factors centered on diagnostic innovation, expanding clinical use cases, and evolving consumer expectations. Technological advances in pediatric cardiac imaging-particularly the widespread adoption of 3D echocardiography, high-field cardiac MRI, and hybrid imaging techniques-are significantly improving early detection rates and diagnostic precision, thereby expanding market penetration. From an end-use perspective, the growing prevalence of pediatric specialty hospitals, fetal cardiology programs, and pediatric oncology centers is increasing demand for high-resolution and multiparametric diagnostic tools. Another key driver is the rising integration of genetic and molecular diagnostics into cardiology workflows, enabling proactive identification of tumor predispositions and associated syndromes. Healthcare providers are also investing heavily in cloud-based image management systems and AI-enhanced analytics platforms, which support collaborative diagnostics, reduce interpretation errors, and streamline reporting across multisite healthcare networks. Increasing clinician awareness and continuous education programs on rare pediatric cardiac presentations are boosting the frequency and accuracy of referrals for diagnostic imaging. Furthermore, the acceleration of newborn and prenatal screening initiatives is bringing cardiac tumors into the diagnostic spotlight at much earlier stages, leading to more favorable intervention windows. On the consumer front, parents are becoming more engaged in pediatric health decisions and increasingly expect swift, non-invasive, and accurate diagnostic options-a trend that is shaping procurement priorities and patient pathway designs. Additionally, rising investments in pediatric research and international collaborations are promoting the development of evidence-based diagnostic guidelines, which in turn are influencing equipment upgrades and protocol standardization across healthcare systems. Collectively, these multifaceted factors are not only catalyzing growth in the pediatric cardiac tumor diagnostics market but are also reshaping how these rare but critical conditions are approached, detected, and managed worldwide.

SCOPE OF STUDY:

The report analyzes the Pediatric Cardiac Tumor Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Tumor (Primary Cardiac Tumors, Secondary Cardiac Tumors); Type (Echocardiography, Magnetic Resonance Imaging, Computed Tomography Scan, Others); End-Use (Hospitals & Clinics, Government Health Department, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â